A study led by Dr. James W. Antoon at Vanderbilt University Medical Center explores oseltamivir's role in reducing serious neuropsychiatric events in pediatric patients with influenza. The research, analyzing data from 692,295 patients, found treatment significantly lowered event risk—0.53 times lower during infection and 0.42 times lower post-treatment—compared to untreated cases. Despite the low absolute risk of 6.25 events per 100,000 weeks, findings emphasize the importance of oseltamivir in managing influenza complications, highlighting the need for careful monitoring of neuropsychiatric symptoms.

Source: JAMA Neurology